William J Sasiela

William J Sasiela

UNVERIFIED PROFILE

Are you William J Sasiela?   Register this Author

Register author
William J Sasiela

William J Sasiela

Publications by authors named "William J Sasiela"

Are you William J Sasiela?   Register this Author

25Publications

960Reads

15Profile Views

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.

Circulation 2019 Aug 27;140(6):470-486. Epub 2019 Jun 27.

Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (R.L.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686956PMC
August 2019

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

N Engl J Med 2018 11 7;379(22):2097-2107. Epub 2018 Nov 7.

From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) - all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and Regeneron Pharmaceuticals, Tarrytown (R.P., W.J.S.) - both in New York; Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); the Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham (V.A.B.); Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Sanofi, Bridgewater, NJ (J.M.E., A.M., J.-F.T.); the Canadian VIGOUR Centre, University of Alberta, Edmonton, and St. Michael's Hospital, University of Toronto, Toronto - both in Canada (S.G.G.); Stanford Center for Clinical Research, Department of Medicine, Stanford University, Stanford, CA (R.A.H., K.W.M.); the Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands (J.W.J.); Duke Clinical Research Institute, Duke University Medical Center (K.Q., M.T.R., P.T.), and the Division of Cardiology, Department of Medicine, Duke University School of Medicine (M.T.R.), Durham, NC; Green Lane Cardiovascular Services, Auckland City Hospital, Auckland, New Zealand (H.D.W.); and the Department of Medicine III, Goethe University, Frankfurt am Main, Germany (A.M.Z.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1801174
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1801174DOI Listing
November 2018

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

JAMA Cardiol 2017 09;2(9):959-966

Program Direction, Cardiovascular and Metabolism, Regeneron Pharmaceuticals, Inc, Tarrytown, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamacardio.2017.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710173PMC
September 2017

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

N Engl J Med 2017 07 24;377(3):211-221. Epub 2017 May 24.

From Regeneron Genetics Center (F.E.D., C.O., C.S., O.G., S.M., C.V.V.H., S.B., L.H., A.L., J.P., N.S., A.J.M., J.D.O., J.G.R., A.R.S., I.B.B., T.M.T., G.D.Y., S.J.M., A. Baras) and Regeneron Pharmaceuticals (V.G., H.M.D., A.Z., W.S., N.S., A.J.M., S.H., A. Bouzelmat, R.Z., B.S., R.P., D.G., G.A.H., W.J.S., P.B., G.D.Y., S.J.M., J.G.) Tarrytown, NY; the Department of Medicine, Division of Translational Medicine and Human Genetics (R.L.D.), and Departments of Surgery (S.D.) and Genetics and Medicine (A.S., D.J.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, and Geisinger Health System, Danville (J.B.L., M.F.M., M.D.R., H.L.K., D.H.L., D.J.C.) - both in Pennsylvania; the Division of Endocrinology and Metabolism, Department of Internal Medicine (W.H.H.S., I.-T.L.) and Cardiovascular Center (K.-W.L.), Taichung Veterans General Hospital, Institute of Medical Technology, National Chung-Hsing University (W.H.H.S.), School of Medicine, Chung Shan Medical University (I.-T.L.), and the Department of Medicine, China Medical University (K.-W.L.), Taichung, and School of Medicine, National Yang-Ming University (W.H.H.S., I.-T.L., K.-W.L.), and School of Medicine, National Defense Medical Center (W.H.H.S.), Taipei - all in Taiwan; Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute and Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA (X.G., J.I.R., Y.-D.I.C.); the Division of Cardiology, Department of Medicine, Molecular Physiology Institute, School of Medicine, Duke University, Durham, NC (W.E.K., S.H.S.); the Department of Clinical Biochemistry, Rigshospitalet (A.B.W., B.G.N., A.T.-H.), the Copenhagen General Population Study (B.G.N., A.T.-H.) and Department of Clinical Biochemistry (B.G.N.), Herlev and Gentofte Hospital, and the Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, and Faculty of Health and Medical Sciences, University of Copenhagen (B.G.N., A.T.-H.) - all in Copenhagen; and TNO Metabolic Health Research, Gaubius Laboratory, Leiden, the Netherlands (A.M.H., H.M.G.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800308PMC
July 2017

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

J Am Coll Cardiol 2017 Feb;69(5):471-482

Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2016.11.037DOI Listing
February 2017

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Am J Cardiol 2017 Jan 29;119(1):40-46. Epub 2016 Sep 29.

Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2016.09.010DOI Listing
January 2017

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Circulation 2017 Jan 16;135(4):352-362. Epub 2016 Dec 16.

From Columbia University College of Physicians and Surgeons, New York (G.R.-S., M.P., C.N., T.T., S.H., R.R., W.K., R.N., N.F., H.N.G.); The City University of New York (J.O.); Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle (S.M.M.); Cardiovascular Nutrition Laboratory, JM USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA (A.H.L., N.R.M.); Sanofi, Bridgewater, NJ (J.M., B.S., L.C., H.K.S.); Umanis, Levallois-Perret, France (M.M.); Sanofi, Montpellier, France (F.B.); Sanofi, Paris, France (F.P.); and Regeneron Pharmaceuticals, Inc., Tarrytown, NY (W.J.S.).

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.0
Publisher Site
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262523PMC
January 2017

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.

Nat Clin Pract Cardiovasc Med 2008 Aug 27;5(8):497-505. Epub 2008 May 27.

Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ncpcardio1250
Publisher Site
http://dx.doi.org/10.1038/ncpcardio1250DOI Listing
August 2008

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

N Engl J Med 2005 Jan;352(1):29-38

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa042000DOI Listing
January 2005

High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.

Circulation 2004 Sep 7;110(11):1406-12. Epub 2004 Sep 7.

Vascular Medicine Program, Department of Medicine, University of California San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093-0682, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.CIR.0000141728.23033.B5DOI Listing
September 2004

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

Circulation 2003 Sep 15;108(13):1560-6. Epub 2003 Sep 15.

Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.CIR.0000091404.09558.AFDOI Listing
September 2003